Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02712736 · ClinicalTrials.gov registry record · NA

Quality of Life in Patients With Primary Sclerosing Cholangitis

A NA study of Primary Sclerosing Cholangitis, sponsored by Duke University.

Completed
Registry status
NA
Development phase
102
Enrollment target
1
Study location

NCT02712736 is a NA study of Primary Sclerosing Cholangitis that has completed, run by Duke University. The registered enrollment target is 102 participants, below the 548-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02712736, a NA study of Primary Sclerosing Cholangitis, has completed, sponsored by Duke University.

COMPLETED
Registry status
NA
Development phase
102 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the healthcare-related quality of life (HRQOL), the impact of risk of liver transplant and risk of malignancy on HRQOL, and the complementary and alternative medicine use in patients with PSC.

Interventions

  • OTHER quality of life survey

Study Locations (1)

North Carolina

  • Duke University - Durham

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2016-07-01
Est. Completion 2018-09-22
Phase NA

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT02712736

The ClinicalTrials.gov registry entry for NCT02712736 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 548-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (81% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Primary Sclerosing Cholangitis appearing as the primary indexed condition, and to 1 intervention - of which quality of life survey is the first listed.

NCT02712736 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT02712736 about?

NCT02712736 is a clinical study titled "Quality of Life in Patients With Primary Sclerosing Cholangitis". The purpose of this study is to assess the healthcare-related quality of life (HRQOL), the impact of risk of liver transplant and risk of malignancy on HRQOL, and the complementary and alternative medicine use in patients with PSC.

What is the current status of trial NCT02712736?

This trial is currently completed. It is a NA study. The enrollment target is 102 participants. The study started on 2016-07-01. Estimated completion is 2018-09-22.

What conditions does trial NCT02712736 study?

This clinical trial studies the following conditions: Primary Sclerosing Cholangitis.

What interventions are being tested in trial NCT02712736?

The interventions under investigation include: quality of life survey (OTHER).

Who is sponsoring clinical trial NCT02712736?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02712736 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Primary Sclerosing Cholangitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.